Get the Stockscreener App
59.43
2.32%
1.35
After Hours:
59.30
-0.13
-0.22%
Tarsus Pharmaceuticals Inc stock is traded at $59.43, with a volume of 573.05K.
It is up +2.32% in the last 24 hours and up +1.45% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$58.08
Open:
$58.14
24h Volume:
573.05K
Relative Volume:
0.87
Market Cap:
$2.51B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-12.81
EPS:
-4.64
Net Cash Flow:
$-123.00M
1W Performance:
+6.83%
1M Performance:
+1.45%
6M Performance:
+15.69%
1Y Performance:
+80.69%
1-Day Range:
$57.91
$59.77
1-Week Range:
$54.16
$59.77
52-Week Range:
$31.66
$59.77
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
59.43 | 2.45B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-27-25 | Resumed | H.C. Wainwright | Buy |
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Tarsus Pharmaceuticals stock hits 52-week high at 59.76 USD - Investing.com India
Is Tarsus Pharmaceuticals Inc a good long term investmentTrendline Breakouts & Watch Expert Picks Before They Rally - earlytimes.in
Tarsus Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
How Tarsus Pharmaceuticals Inc. stock reacts to inflationary pressuresBull Run & Free Safe Entry Trade Signal Reports - newser.com
Why Tarsus Pharmaceuticals Inc. stock attracts high net worth investorsNew Guidance & Verified Momentum Watchlists - newser.com
What drives Tarsus Pharmaceuticals Inc stock priceDividend Reinvestment Plans & Subscribe for Free Weekly Winners - earlytimes.in
Is Tarsus Pharmaceuticals Inc. forming a bottoming baseJuly 2025 Closing Moves & Proven Capital Preservation Tips - newser.com
Azamian, Tarsus Pharmaceuticals CEO, sells $332k in stock By Investing.com - Investing.com Nigeria
Azamian, Tarsus Pharmaceuticals CEO, sells $332k in stock - Investing.com India
Bobak Azamian Sells 6,000 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock - MarketBeat
Tarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay Off (NASDAQ:TARS) - Seeking Alpha
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
5,600 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by Strs Ohio - MarketBeat
Assenagon Asset Management S.A. Sells 127,718 Shares of Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Aug Ideas: What is the long term forecast for Tarsus Pharmaceuticals Inc stockJuly 2025 Rallies & Daily Volume Surge Signals - خودرو بانک
Bond Watch: Why is Tarsus Pharmaceuticals Inc stock going downJuly 2025 Levels & Consistent Growth Stock Picks - خودرو بانک
Tarsus Pharmaceuticals gains amid takeover speculation - MSN
Hedge Fund Bets: Is Tarsus Pharmaceuticals Inc. stock forming a triangle pattern2025 AllTime Highs & Risk Controlled Stock Pick Alerts - خودرو بانک
Published on: 2025-09-20 01:31:03 - خودرو بانک
What is the long term forecast for Tarsus Pharmaceuticals Inc stockMarket Activity Recap & Safe Entry Momentum Tips - خودرو بانک
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Woodline Partners LP - MarketBeat
Can you recover from losses in Tarsus Pharmaceuticals Inc.July 2025 Decliners & Advanced Technical Signal Analysis - newser.com
Aug Volume: Is Tarsus Pharmaceuticals Inc exposed to currency risksJuly 2025 Action & Fast Gaining Stock Reports - خودرو بانک
Using data tools to time your Tarsus Pharmaceuticals Inc. exitPortfolio Value Summary & High Yield Stock Recommendations - newser.com
Using Bollinger Bands to evaluate Tarsus Pharmaceuticals Inc.Watch List & Momentum Based Trading Ideas - newser.com
Rhumbline Advisers Raises Position in Tarsus Pharmaceuticals, Inc. $TARS - Defense World
Tarsus Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Investment Report: Why is Xos Inc. stock going down2025 Technical Patterns & Daily Volume Surge Trade Alerts - خودرو بانک
Tarsus Pharmaceuticals seesaws amid report Alcon interest has cooled - MSN
Quarterly Recap: What is the long term forecast for Tarsus Pharmaceuticals Inc. stockJuly 2025 Macro Moves & Safe Capital Growth Plans - خودرو بانک
Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 4.1% on Insider Selling - MarketBeat
IPO Launch: What is Tarsus Pharmaceuticals Incs P E ratio telling us2025 Key Highlights & Daily Market Momentum Tracking - خودرو بانک
Growth Value: Does Tarsus Pharmaceuticals Inc have declining or rising EPS2025 Support & Resistance & AI Enhanced Execution Alerts - khodrobank.com
Sectors Review: Will Tarsus Pharmaceuticals Inc benefit from rising consumer demandMarket Trend Summary & Real-Time Volume Spike Alerts - خودرو بانک
Market Outlook: Will Tarsus Pharmaceuticals Inc benefit from green energy policiesJuly 2025 Intraday Action & High Conviction Buy Zone Alerts - خودرو بانک
Market Moves: Will Tarsus Pharmaceuticals Inc benefit from green energy policiesJuly 2025 Momentum & Consistent Return Investment Signals - خودرو بانک
Regression analysis insights on Tarsus Pharmaceuticals Inc. performanceJuly 2025 Price Swings & Reliable Price Breakout Signals - newser.com
Aug Patterns: Does Tarsus Pharmaceuticals Inc have declining or rising EPSQuarterly Profit Report & Weekly Stock Breakout Alerts - خودرو بانک
Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Director Sells 27,116 Shares of Stock - MarketBeat
Advanced analytics toolkit walkthrough for Tarsus Pharmaceuticals Inc.Market Activity Summary & Smart Allocation Stock Tips - newser.com
Will Tarsus Pharmaceuticals Inc. benefit from macro trendsM&A Rumor & Long-Term Safe Investment Ideas - newser.com
Surprises Report: Can VirnetX Holding Corporation generate free cash flowGDP Growth & Growth Focused Entry Reports - خودرو بانک
How institutional ownership impacts Tarsus Pharmaceuticals Inc. stockNew Guidance & AI Powered Market Trend Analysis - newser.com
Have Insiders Sold Tarsus Pharmaceuticals Shares Recently? - 富途牛牛
Adage Capital Partners GP L.L.C. Purchases Shares of 510,000 Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharma director Link sells $1.55m in stock By Investing.com - Investing.com Australia
Tarsus Pharma director Link sells $1.55m in stock - Investing.com
Baird Financial Group Inc. Decreases Stock Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):